Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20908217 | 1.00 | TACR1 (0.37) | TACR1MEN1KMT2ACTSSAAK1 | |
| SCHEMBL21112351 | 0.89 | MEN1 (0.40) | TACR1MEN1KMT2ACTSSAAK1 | |
| SCHEMBL21112347 | 0.89 | MEN1 (0.40) | TACR1MEN1KMT2ACTSSAAK1 | |
| SCHEMBL20908216 | 0.82 | MMP1 (0.36) | TACR1MEN1KMT2ACTSSAAK1 | |
| SCHEMBL29640227 | 0.82 | MMP1 (0.36) | TACR1MEN1KMT2ACTSSAAK1 | |
| SCHEMBL29640241 | 0.82 | MEN1 (0.37) | TACR1MEN1KMT2ACTSSAAK1 | |
| SCHEMBL28407708 | 0.82 | MEN1 (0.37) | TACR1MEN1KMT2ACTSSAAK1 | |
| SCHEMBL20907560 | 0.82 | MEN1 (0.37) | TACR1MEN1KMT2ACTSSAAK1 | |
| SCHEMBL23114825 | 0.81 | MEN1 (0.38) | TACR1MEN1KMT2ACTSSAAK1 | |
| SCHEMBL20907561 | 0.81 | PLAU (0.39) | TACR1MEN1KMT2ACTSSAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352329-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352329-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210078959-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078959-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, FURIN | TACR1 1109/4885MEN1 2814/4885KMT2A 1556/4885 |
| US-11352329-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | TACR1 1109/4885MEN1 2814/4885KMT2A 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.